Hepatocellular carcinoma mouse models: Hepatitis B virusassociated hepatocarcinogenesis and haploinsufficient tumor suppressor genes

World Journal of Gastroenterology

Volumn 22, Issue 1, 2016, Pages 300-325

  Teng, Yuan Chi ^a   Shen, Zhao Qing ^a   Kao, Cheng Heng ^b   Tsai, Ting Fen ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Haploinsufficiency; Hepatitis B virus; Hepatocellular carcinoma; Mouse models; Tumor suppressor genes

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; ANNEXIN; AUTOPHAGY PROTEIN 5; BECLIN 1; CORE PROTEIN; CYTOKINE; FARNESOID X RECEPTOR; FODRIN; GALECTIN 3; GLYCOPROTEIN; KRUPPEL LIKE FACTOR 6; MAMMALIAN TARGET OF RAPAMYCIN; MEMBRANE PROTEIN; MICRORNA; MICRORNA 122; MICRORNA 140; NIBRIN; NUCLEAR RECEPTOR COACTIVATOR; NUCLEAR RECEPTOR COACTIVATOR 2; PARKIN; POLO LIKE KINASE 4; PROTEIN KINASE B; PROTEIN P21; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TELOMERASE INHIBITOR; TRANSCRIPTION FACTOR NF E2; TRANSFORMING GROWTH FACTOR BETA2; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOID CYSTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CELL CYCLE; COLON POLYPOSIS; GENETICALLY ENGINEERED MOUSE STRAIN; GENOMIC INSTABILITY; HAPLOINSUFFICIENCY; HEPATITIS B VIRUS; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; MOUSE MODEL; MULTIDRUG RESISTANCE; NEUROFIBROMATOSIS TYPE 2; NONHUMAN; REGULATOR GENE; RISK FACTOR; TUMOR SUPPRESSOR GENE; UBIQUITINATION; WNT SIGNALING PATHWAY; ANIMAL; COCARCINOGENESIS; EXPERIMENTAL LIVER NEOPLASM; GENETICS; HUMAN; LIVER TUMOR; PATHOGENICITY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ULTRASTRUCTURE; VIROLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; COCARCINOGENESIS; GENES, TUMOR SUPPRESSOR; HAPLOINSUFFICIENCY; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84953396287     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i1.300     Document Type: Article

References (246)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.e1 [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061]
2. Bakiri L, Wagner EF. Mouse models for liver cancer. Mol Oncol 2013; 7: 206-223 [PMID: 23428636 DOI: 10.1016/j.molonc.2013.01.005]
3. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014; 28: 753-770 [PMID: 25260306 DOI: 10.1016/j.bpg.2014.08.007]
4. Li Y, Tang ZY, Hou JX. Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol 2012; 9: 32-43 [PMID: 22025031 DOI: 10.1038/nrgastro.2011.196]
5. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346 [PMID: 12149612 DOI: 10.1038/ng0802-339]
6. Cougot D, Neuveut C, Buendia MA. HBV induced carcinogenesis. J Clin Virol 2005; 34 Suppl 1: S75-S78 [PMID: 16461228 DOI: 10.1016/S1386-6532(05)80014-9]
7. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 2006; 25: 3823-3833 [PMID: 16799624 DOI: 10.1038/sj.onc.1209559]
8. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-121 [PMID: 18505690 DOI: 10.1053/j.gastro.2008.03.073]
9. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218 DOI: 10.1001/jama.295.1.65]
10. Tan A, Yeh SH, Liu CJ, Cheung C, Chen PJ. Viral hepatocarcinogenesis: from infection to cancer. Liver Int 2008; 28: 175-188 [DOI: 10.1111/j.1478-3231.2007.01652.x]
11. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002; 21: 2593-2604 [PMID: 11971194 DOI: 10.1038/sj.onc.1205434]
12. Halegoua-De Marzio D, Hann HW. Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol 2014; 20: 401-413 [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401]
13. Milich DR, Jones JE, Hughes JL, Maruyama T, Price J, Melhado I, Jirik F. Extrathymic expression of the intracellular hepatitis B core antigen results in T cell tolerance in transgenic mice. J Immunol1994; 152: 455-466 [PMID: 8283030]
14. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229 [PMID: 15738952 DOI: 10.1038/nri1573]
15. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011; 8: 275-284 [PMID: 21423260 DOI: 10.1038/nrgastro.2011.33]
16. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV-And HCV-Associated hepatocellular carcinoma. Nat Rev Cancer 2013; 13: 123-135 [PMID: 23344543 DOI: 10.1038/nrc3449]
17. Ilan E, Burakova T, Dagan S, Nussbaum O, Lubin I, Eren R, Ben-Moshe O, Arazi J, Berr S, Neville L, Yuen L, Mansour TS, Gillard J, Eid A, Jurim O, Shouval D, Reisner Y, Galun E. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology 1999; 29: 553-562 [PMID: 9918935 DOI: 10.1002/hep.510290228]
18. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013; 310: 974-976 [PMID: 24002285 DOI: 10.1001/jama.2013.276701]
19. Hudu SA, Malik YA, Niazlin MT, Harmal NS, Sekawi Z. An Overview of Hepatitis B Virus Surface Antigen Mutant in the Asia Pacific. Curr Issues Mol Biol 2014; 16: 69-78 [PMID: 24014801]
20. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1: e00049 [PMID: 23150796 DOI: 10.7554/eLife.00049]
21. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R, Sültmann H, Urban S. Hepatitis B and D viruses exploit sodium taurocholate cotransporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014; 146: 1070-1083 [PMID: 24361467 DOI: 10.1053/j.gastro.2013.12.024]
22. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, Brinster RL, Palmiter RD. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 1145-1156 [PMID: 2598264 DOI: 10.1016/0092-8674(89)90770-8]
23. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987; 56: 651-693 [PMID: 3039907 DOI: 10.1146/annurev.bi.56.070187.003251]
24. Moolla N, Kew M, Arbuthnot P. Regulatory elements of hepatitis B virus transcription. J Viral Hepat 2002; 9: 323-331 [PMID: 12225325 DOI: 10.1046/j.1365-2893.2002.00381.x]
25. Inuzuka T, Takahashi K, Chiba T, Marusawa H. Mouse models of hepatitis B virus infection comprising host-virus immunologic interactions. Pathogens 2014; 3: 377-389 [PMID: 25437805 DOI: 10.3390/pathogens3020377]
26. Araki K, Nishimura S, Ochiya T, Okubo K, Miyazaki J, Matsubara K, Yamamura K. Production and effect of infectious Dane particles in transgenic mice. Jpn J Cancer Res 1991; 82: 235-239 [PMID: 1902445 DOI: 10.1111/j.1349-7006.1991.tb01834.x]
27. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997; 71: 3236-3243 [PMID: 9060687 DOI: 10.1128/JVI.76.21.10702-10707. 2002]
28. Babinet C, Farza H, Morello D, Hadchouel M, Pourcel C. Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. Science 1985; 230: 1160-1163 [PMID: 3865370 DOI: 10.1126/science.3865370]
29. Chisari FV, Pinkert CA, Milich DR, Filippi P, McLachlan A, Palmiter RD, Brinster RL. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985; 230: 1157-1160 [PMID: 3865369 DOI: 10.1126/science.3865369]
30. Chisari FV, Filippi P, McLachlan A, Milich DR, Riggs M, Lee S, Palmiter RD, Pinkert CA, Brinster RL. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol 1986; 60: 880-887 [PMID: 3783819]
31. Chisari FV, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA, Palmiter RD, Brinster RL. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 1987; 84: 6909-6913 [PMID: 3477814 DOI: 10.1073/pnas.84.19.6909]
32. Toshkov I, Chisari FV, Bannasch P. Hepatic preneoplasia in hepatitis B virus transgenic mice. Hepatology 1994; 20: 1162-1172 [PMID: 7927248 DOI: 10.1002/hep.1840200510]
33. Wang HC, Chang WT, Chang WW, Wu HC, Huang W, Lei HY, Lai MD, Fausto N, Su IJ. Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes. Hepatology 2005; 41: 761-770 [PMID: 15726643 DOI: 10.1002/hep.20615]
34. Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 1990; 50: 3400-3407 [PMID: 1692259]
35. DeLoia JA, Burk RD, Gearhart JD. Developmental regulation of hepatitis B surface antigen expression in two lines of hepatitis B virus transgenic mice. J Virol 1989; 63: 4069-4073 [PMID: 2760988]
36. Farza H, Salmon AM, Hadchouel M, Moreau JL, Babinet C, Tiollais P, Pourcel C. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice. Proc Natl Acad Sci USA 1987; 84: 1187-1191 [PMID: 3469661 DOI: 10.1073/pnas.84.5.1187]
37. Wang Y, Cui F, Lv Y, Li C, Xu X, Deng C, Wang D, Sun Y, Hu G, Lang Z, Huang C, Yang X. HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice. Hepatology 2004; 39: 318-324 [PMID: 14767984 DOI: 10.1002/hep.20076]
38. Su IJ, Wang LH, Hsieh WC, Wu HC, Teng CF, Tsai HW, Huang W. The emerging role of hepatitis B virus pre-S2 deletion mutant proteins in HBV tumorigenesis. J Biomed Sci 2014; 21: 98 [PMID: 25316153 DOI: 10.1186/s12929-014-0098-7]
39. Abe K, Thung SN, Wu HC, Tran TT, Le Hoang P, Truong KD, Inui A, Jang JJ, Su IJ. Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci 2009; 100: 2249-2254 [PMID: 19719772 DOI: 10.1111/j.1349-7006.2009.01309.x]
40. Wang HC, Huang W, Lai MD, Su IJ. Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci 2006; 97: 683-688 [PMID: 16863502 DOI: 10.1111/j.1349-7006.2006.00235.x]
41. Yu DY, Moon HB, Son JK, Jeong S, Yu SL, Yoon H, Han YM, Lee CS, Park JS, Lee CH, Hyun BH, Murakami S, Lee KK. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol 1999; 31: 123-132 [PMID: 10424292 DOI: 10.1016/S0168-8278(99)80172-X]
42. Lee TH, Finegold MJ, Shen RF, DeMayo JL, Woo SL, Butel JS. Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice. J Virol 1990; 64: 5939-5947 [PMID: 2243380]
43. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-320 [PMID: 2034275 DOI: 10.1038/351317a0]
44. Koike K, Moriya K, Iino S, Yotsuyanagi H, Endo Y, Miyamura T, Kurokawa K. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 1994; 19: 810-819 [PMID: 8138251 DOI: 10.1002/hep.1840190403]
45. Lu JW, Hsia Y, Yang WY, Lin YI, Li CC, Tsai TF, Chang KW, Shieh GS, Tsai SF, Wang HD, Yuh CH. Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis 2012; 33: 209-219 [PMID: 22021908 DOI: 10.1093/carcin/bgr224]
46. Wu BK, Li CC, Chen HJ, Chang JL, Jeng KS, Chou CK, Hsu MT, Tsai TF. Blocking of G1/S transition and cell death in the regenerating liver of Hepatitis B virus X protein transgenic mice. Biochem Biophys Res Commun 2006; 340: 916-928 [PMID: 16403455 DOI: 10.1016/j.bbrc.2005.12.089]
47. Wu YF, Fu SL, Kao CH, Yang CW, Lin CH, Hsu MT, Tsai TF. Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice. Cancer Res 2008; 68: 2033-2042 [PMID: 18339886 DOI: 10.1158/0008-5472.CAN-07-2450]
48. Geng X, Harry BL, Zhou Q, Skeen-Gaar RR, Ge X, Lee ES, Mitani S, Xue D. Hepatitis B virus X protein targets the Bcl-2 protein CED-9 to induce intracellular Ca2+ increase and cell death in Caenorhabditis elegans. Proc Natl Acad Sci USA 2012; 109: 18465-18470 [PMID: 23091037 DOI: 10.1073/pnas.1204652109]
49. Geng X, Huang C, Qin Y, McCombs JE, Yuan Q, Harry BL, Palmer AE, Xia NS, Xue D. Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction. Proc Natl Acad Sci USA 2012; 109: 18471-18476 [PMID: 23091012 DOI: 10.1073/pnas.1204668109]
50. Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF, Chang KY, Huang WC, Lin PW, Chiang CW, Chang TT. Hepatitis B virus X protein upregulates mTOR signaling through IKK? to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One 2012; 7: e41931 [PMID: 22848663 DOI: 10.1371/journal. pone.0041931]
51. Lan SH, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS. Autophagy-preferential degradation of MIR224 participates in hepatocellular carcinoma tumorigenesis. Autophagy 2014; 10: 1687-1689 [PMID: 25068270 DOI: 10.4161/auto.29959]
52. Lan SH, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS. Autophagy suppresses tumorigenesis of hepatitis B virus-Associated hepatocellular carcinoma through degradation of microRNA-224. Hepatology 2014; 59: 505-517 [PMID: 23913306 DOI: 10.1002/hep.26659]
53. Teng CF, Hsieh WC, Yang CW, Su HM, Tsai TF, Sung WC, Huang W, Su IJ. A biphasic response pattern of lipid metabolomics in the stage progression of hepatitis B virus X tumorigenesis. Mol Carcinog 2015; Epub ahead of print [PMID: 25594851 DOI: 10.1002/mc.22266]
54. Lin HC, Chen YF, Hsu WH, Yang CW, Kao CH, Tsai TF. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev Res (Phila) 2012; 5: 952-962 [PMID: 22659145 DOI: 10.1158/1940-6207.CAPR-12-0001]
55. Hsieh WC, Yang CW, Haung YS, Chao TW, Tsai TF, Su IJ. Chemoprevention of HBV-related hepatocellular carcinoma by the combined product of resveratrol and silymarin in transgenic mice. Funct Foods Heal Dis 2013; 3: 341-352
56. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero Proc Natl Acad Sci USA 1990; 87: 6599-6603 [PMID: 2395863 DOI: 10.1073/pnas.87.17.6599]
57. Takashima H, Araki K, Miyazaki J, Yamamura K, Kimoto M. Characterization of T-cell tolerance to hepatitis B virus (HBV) antigen in transgenic mice. Immunology 1992; 75: 398-405 [PMID: 1533387]
58. Guidotti LG, Martinez V, Loh YT, Rogler CE, Chisari FV. Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice. J Virol 1994; 68: 5469-5475 [PMID: 8057429]
59. Yamamura K, Araki K, Hino O, Tomita N, Miyazaki J, Matsubara K. HBV production in transgenic mice. Gastroenterol Jpn 1990; 25 Suppl 2: 49-52 [PMID: 2227265 DOI: 10.1007/BF02779928]
60. Farza H, Hadchouel M, Scotto J, Tiollais P, Babinet C, Pourcel C. Replication and gene expression of hepatitis B virus in a transgenic mouse that contains the complete viral genome. J Virol 1988; 62: 4144-4152 [PMID: 2845128]
61. Araki K, Miyazaki J, Hino O, Tomita N, Chisaka O, Matsubara K, Yamamura K. Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci USA 1989; 86: 207-211 [PMID: 2911569 DOI: 10.1073/pnas.86.1.207]
62. Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. J Virol 1995; 69: 6158-6169 [PMID: 7666518]
63. Guidotti LG, Eggers CM, Raney AK, Chi SY, Peters JM, Gonzalez FJ, McLachlan A. In vivo regulation of hepatitis B virus replication by peroxisome proliferators. J Virol 1999; 73: 10377-10386 [PMID: 10559356]
64. Chen SH, Wu HL, Kao JH, Hwang LH. Persistent hepatitis B viral replication in a FVB/N mouse model: impact of host and viral factors. PLoS One 2012; 7: e36984 [PMID: 22615863 DOI: 10.1371/journal.pone.0036984]
65. Grompe M, Strom S. Mice with human livers. Gastroenterology 2013; 145: 1209-1214 [PMID: 24042096 DOI: 10.1053/j.gastro.2013.09.009]
66. Moriyama T, Guilhot S, Klopchin K, Moss B, Pinkert CA, Palmiter RD, Brinster RL, Kanagawa O, Chisari FV. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990; 248: 361-364 [PMID: 1691527 DOI: 10.1126/science.1691527]
67. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188: 341-350 [PMID: 9670046 DOI: 10.1084/jem.188.2.341]
68. Raney AK, Eggers CM, Kline EF, Guidotti LG, Pontoglio M, Yaniv M, McLachlan A. Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice. J Virol 2001; 75: 2900-2911 [PMID: 11222715 DOI: 10.1128/JVI.75.6.2900-2911.2001]
69. Julander JG, Sidwell RW, Morrey JD. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res 2002; 55: 27-40 [PMID: 12076749]
70. Fan HX, Tang H. Complex interactions between microRNAs and hepatitis B/C viruses. World J Gastroenterol 2014; 20: 13477-13492 [PMID: 25309078 DOI: 10.3748/wjg.v20.i37.13477]
71. Kennedy EM, Bassit LC, Mueller H, Kornepati AV, Bogerd HP, Nie T, Chatterjee P, Javanbakht H, SChinazi RF, Cullen BR. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 2015; 476: 196-205 [PMID: 25553515 DOI: 10.1016/j.virol.2014.12.001]
72. Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC, Lin YY, Wang HY, Wang CC, Shen YC, Wu FY, Kao JH, Chen DS, Chen PJ. The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids 2014; 3: e186 [PMID: 25137139 DOI: 10.1038/mtna.2014.38]
73. Seeger C, Sohn JA. Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids 2014; 3: e216 [PMID: 25514649 DOI: 10.1038/mtna.2014.68]
74. Martin J, Dufour JF. Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1720-1733 [PMID: 18350603 DOI: 10.3748/wjg.14.1720]
75. Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis 2010; 30: 75-86 [PMID: 20175035 DOI: 10.1055/s-0030-1247134]
76. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo F, Zucman-Rossi J. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44: 694-698 [PMID: 22561517 DOI: 10.1038/ng.2256]
77. Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, Willard MD, Xu J, Hauptschein R, Rejto PA, Fernandez J, Wang G, Zhang Q, Wang B, Chen R, Wang J, Lee NP, Zhou W, Lin Z, Peng Z, Yi K, Chen S, Li L, Fan X, Yang J, Ye R, Ju J, Wang K, Estrella H, Deng S, Wei P, Qiu M, Wulur IH, Liu J, Ehsani ME, Zhang C, Loboda A, Sung WK, Aggarwal A, Poon RT, Fan ST, Wang J, Hardwick J, Reinhard C, Dai H, Li Y, Luk JM, Mao M. Wholegenome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 2013; 23: 1422-1433 [PMID: 23788652 DOI: 10.1101/gr.154492.113]
78. Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis 2005; 26: 2031-2045 [PMID: 16150895 DOI: 10.1093/carcin/bgi223]
79. Smilenov LB. Tumor development: haploinsufficiency and local network assembly. Cancer Lett 2006; 240: 17-28 [PMID: 16223564 DOI: 10.1016/j.canlet.2005.08.015]
80. Berger AH, Pandolfi PP. Haplo-insufficiency: a driving force in cancer. J Pathol 2011; 223: 137-146 [PMID: 21125671 DOI: 10.1002/path.2800]
81. Cui J, Gong Z, Shen HM. The role of autophagy in liver cancer: molecular mechanisms and potential therapeutic targets. Biochim Biophys Acta 2013; 1836: 15-26 [PMID: 23428608 DOI: 10.1016/j.bbcan.2013.02.003]
82. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, Kimmelman A, Kumar S, Levine B, Maiuri MC, Martin SJ, Penninger J, Piacentini M, Rubinsztein DC, Simon HU, Simonsen A, Thorburn AM, Velasco G, Ryan KM, Kroemer G. Autophagy in malignant transformation and cancer progression. EMBO J 2015; 34: 856-880 [PMID: 25712477 DOI: 10.15252/embj.201490784]
83. Rautou PE, Mansouri A, Lebrec D, Durand F, Valla D, Moreau R. Autophagy in liver diseases. J Hepatol 2010; 53: 1123-1134 [PMID: 20810185 DOI: 10.1016/j.jhep.2010.07.006]
84. Ding ZB, Shi YH, Zhou J, Qiu SJ, Xu Y, Dai Z, Shi GM, Wang XY, Ke AW, Wu B, Fan J. Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res 2008; 68: 9167-9175 [PMID: 19010888 DOI: 10.1158/0008-5472.CAN-08-1573]
85. Kotsafti A, Farinati F, Cardin R, Cillo U, Nitti D, Bortolami M. Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma. BMC Gastroenterol 2012; 12: 118 [PMID: 22928777 DOI: 10.1186/1471-230X-12-118]
86. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 2003; 100: 15077-15082 [PMID: 14657337 DOI: 10.1073/pnas.2436255100]
87. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G, Levine B. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112: 1809-1820 [PMID: 14638851 DOI: 10.1172/JCI200320039]
88. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, Ohsumi Y, Tokuhisa T, Mizushima N. The role of autophagy during the early neonatal starvation period. Nature 2004; 432: 1032-1036 [PMID: 15525940 DOI: 10.1038/nature03029]
89. Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N, Ohsumi Y, Uchiyama Y, Kominami E, Tanaka K, Chiba T. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol 2005; 169: 425-434 [PMID: 15866887 DOI: 10.1083/jcb.200412022]
90. An CH, Kim MS, Yoo NJ, Park SW, Lee SH. Mutational and expressional analyses of ATG5, an autophagy-related gene, in gastrointestinal cancers. Pathol Res Pract 2011; 207: 433-437 [PMID: 21664058 DOI: 10.1016/j.prp.2011.05.002]
91. Ni HM, Woolbright BL, Williams J, Copple B, Cui W, Luyendyk JP, Jaeschke H, Ding WX. Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. J Hepatol 2014; 61: 617-625 [PMID: 24815875 DOI: 10.1016/j.jhep.2014.04.043]
92. Chang Y, Yan W, He X, Zhang L, Li C, Huang H, Nace G, Geller DA, Lin J, Tsung A. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology 2012; 143: 177-187.e8 [PMID: 22504094 DOI: 10.1053/j.gastro.2012.04.009]
93. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, Eishi Y, Hino O, Tanaka K, Mizushima N. Autophagy-deficient mice develop multiple liver tumors. Genes Dev 2011; 25: 795-800 [PMID: 21498569 DOI: 10.1101/gad.2016211]
94. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Tanaka K, Cuervo AM, Czaja MJ. Autophagy regulates lipid metabolism. Nature 2009; 458: 1131-1135 [PMID: 19339967 DOI: 10.1038/nature07976]
95. Williams GH, Stoeber K. The cell cycle and cancer. J Pathol 2012; 226: 352-364 [PMID: 21990031 DOI: 10.1002/path.3022]
96. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]
97. Andreoli V, Gehrau RC, Bocco JL. Biology of Krüppel-like factor 6 transcriptional regulator in cell life and death. IUBMB Life 2010; 62: 896-905 [PMID: 21154818 DOI: 10.1002/iub.396]
98. Tetreault MP, Yang Y, Katz JP. Krüppel-like factors in cancer. Nat Rev Cancer 2013; 13: 701-713 [PMID: 24060862 DOI: 10.1038/nrc3582]
99. Tarocchi M, Hannivoort R, Hoshida Y, Lee UE, Vetter D, Narla G, Villanueva A, Oren M, Llovet JM, Friedman SL. Carcinogeninduced hepatic tumors in KLF6+/-mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology 2011; 54: 522-531 [PMID: 21563203 DOI: 10.1002/hep.24413]
100. Vetter D, Cohen-Naftaly M, Villanueva A, Lee YA, Kocabayoglu P, Hannivoort R, Narla G, M Llovet J, Thung SN, Friedman SL. Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology 2012; 56: 1361-1370 [PMID: 22535637 DOI: 10.1002/hep.25810]
101. Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM, Banck M, Zimran E, Thorgeirsson SS, Mazzaferro V, Bruix J, Martignetti JA, Llovet JM, Friedman SL. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol 2007; 46: 645-654 [PMID: 17196295 DOI: 10.1016/j.jhep.2006.10.012]
102. Swallow CJ, Ko MA, Siddiqui NU, Hudson JW, Dennis JW. Sak/Plk4 and mitotic fidelity. Oncogene 2005; 24: 306-312 [PMID: 15640847 DOI: 10.1038/sj.onc.1208275]
103. Hudson JW, Kozarova A, Cheung P, Macmillan JC, Swallow CJ, Cross JC, Dennis JW. Late mitotic failure in mice lacking Sak, a polo-like kinase. Curr Biol 2001; 11: 441-446 [PMID: 11301255 DOI: 10.1016/S0960-9822(01)00117-8]
104. Ko MA, Rosario CO, Hudson JW, Kulkarni S, Pollett A, Dennis JW, Swallow CJ. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet 2005; 37: 883-888 [PMID: 16025114 DOI: 10.1038/ng1605]
105. Pellegrino R, Calvisi DF, Ladu S, Ehemann V, Staniscia T, Evert M, Dombrowski F, Schirmacher P, Longerich T. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 2010; 51: 857-868 [PMID: 20112253 DOI: 10.1002/hep.23467]
106. Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol 2013; 25: 52-58 [PMID: 23159848 DOI: 10.1097/CCO.0b013e32835b639e]
107. Jackson RJ, Engelman RW, Coppola D, Cantor AB, Wharton W, Pledger WJ. p21Cip1 nullizygosity increases tumor metastasis in irradiated mice. Cancer Res 2003; 63: 3021-3025 [PMID: 12810620]
108. Ehedego H, Boekschoten MV, Hu W, Doler C, Haybaeck J, Galer N, Müller M, Liedtke C, Trautwein C. p21 ablation in liver enhances DNA damage, cholestasis, and carcinogenesis. Cancer Res 2015; 75: 1144-1155 [PMID: 25608711 DOI: 10.1158/0008-5472. CAN-14-1356]
109. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331 [PMID: 9039259 DOI: 10.1016/S0092-8674(00)81871-1]
110. Gurpinar E, Vousden KH. Hitting cancers'weak spots: vulnerabilities imposed by p53 mutation. Trends Cell Biol 2015; 25: 486-495 [PMID: 25960041 DOI: 10.1016/j.tcb.2015.04.001]
111. Ghebranious N, Sell S. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology 1998; 27: 383-391 [PMID: 9462635 DOI: 10.1002/hep.510270211]
112. Katz SF, Lechel A, Obenauf AC, Begus-Nahrmann Y, Kraus JM, Hoffmann EM, Duda J, Eshraghi P, Hartmann D, Liss B, Schirmacher P, Kestler HA, Speicher MR, Rudolph KL. Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation. Gastroenterology 2012; 142: 1229-1239.e3 [PMID: 22342966 DOI: 10.1053/j.gastro.2012.02.009]
113. Liu J, Shaik S, Dai X, Wu Q, Zhou X, Wang Z, Wei W. Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta 2015; 1855: 50-60 [PMID: 25481052 DOI: 10.1016/j.bbcan.2014.11.005]
114. Johnson DE. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer 2015; 22: T1-17 [PMID: 24659480 DOI: 10.1530/ERC-14-0005]
115. Lipkowitz S, Weissman AM. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer 2011; 11: 629-643 [PMID: 21863050 DOI: 10.1038/nrc3120]
116. Yin J, Zhu JM, Shen XZ. The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma. Int J Cancer 2015; 136: 249-257 [PMID: 24420637 DOI: 10.1002/ijc.28717]
117. Zhang T, Kho DH, Wang Y, Harazono Y, Nakajima K, Xie Y, Raz A. Gp78, an E3 ubiquitin ligase acts as a gatekeeper suppressing nonalcoholic steatohepatitis (NASH) and liver cancer. PLoS One 2015; 10: e0118448 [PMID: 25789613 DOI: 10.1371/journal. pone.0118448]
118. Fujiwara M, Marusawa H, Wang HQ, Iwai A, Ikeuchi K, Imai Y, Kataoka A, Nukina N, Takahashi R, Chiba T. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 2008; 27: 6002-6011 [PMID: 18574468 DOI: 10.1038/onc.2008.199]
119. Jiang S, Minter LC, Stratton SA, Yang P, Abbas HA, Akdemir ZC, Pant V, Post S, Gagea M, Lee RG, Lozano G, Barton MC. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. J Hepatol 2015; 62: 371-379 [PMID: 25281858 DOI: 10.1016/j.jhep.2014.09.026]
120. Chen Z, Du S, Fang S. gp78: a multifaceted ubiquitin ligase that integrates a unique protein degradation pathway from the endoplasmic reticulum. Curr Protein Pept Sci 2012; 13: 414-424 [PMID: 22812524 DOI: 10.2174/138920312802430590]
121. Xu L, Lin DC, Yin D, Koeffler HP. An emerging role of PARK2 in cancer. J Mol Med (Berl) 2014; 92: 31-42 [PMID: 24297497 DOI: 10.1007/s00109-013-1107-0]
122. Wang F, Denison S, Lai JP, Philips LA, Montoya D, Kock N, Schüle B, Klein C, Shridhar V, Roberts LR, Smith DI. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 2004; 40: 85-96 [PMID: 15101042 DOI: 10.1002/gcc.20020]
123. Kim KY, Stevens MV, Akter MH, Rusk SE, Huang RJ, Cohen A, Noguchi A, Springer D, Bocharov AV, Eggerman TL, Suen DF, Youle RJ, Amar M, Remaley AT, Sack MN. Parkin is a lipidresponsive regulator of fat uptake in mice and mutant human cells. J Clin Invest 2011; 121: 3701-3712 [PMID: 21865652 DOI: 10.1172/JCI44736]
124. Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer 2011; 11: 792-804 [PMID: 21979307 DOI: 10.1038/nrc3139]
125. Liu X, Huang Y, Yang D, Li X, Liang J, Lin L, Zhang M, Zhong K, Liang B, Li J. Overexpression of TRIM24 is associated with the onset and progress of human hepatocellular carcinoma. PLoS One 2014; 9: e85462 [PMID: 24409330 DOI: 10.1371/journal. pone.0085462]
126. Shen Z. Genomic instability and cancer: an introduction. J Mol Cell Biol 2011; 3: 1-3 [PMID: 21278445 DOI: 10.1093/jmcb/mjq057]
127. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-An evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-228 [PMID: 20177397 DOI: 10.1038/nrm2858]
128. Bakhoum SF, Compton DA. Chromosomal instability and cancer: a complex relationship with therapeutic potential. J Clin Invest 2012; 122: 1138-1143 [PMID: 22466654 DOI: 10.1172/JCI59954]
129. Guo C, Liu S, Greenaway F, Sun MZ. Potential role of annexin A7 in cancers. Clin Chim Acta 2013; 423: 83-89 [PMID: 23639634 DOI: 10.1016/j.cca.2013.04.018]
130. Srivastava M, Atwater I, Glasman M, Leighton X, Goping G, Caohuy H, Miller G, Pichel J, Westphal H, Mears D, Rojas E, Pollard HB. Defects in inositol 1,4,5-trisphosphate receptor expression, Ca(2+) signaling, and insulin secretion in the anx7(+/-) knockout mouse. Proc Natl Acad Sci USA 1999; 96: 13783-13788 [PMID: 10570150 DOI: 10.1073/pnas.96.24.13783]
131. Srivastava M, Torosyan Y, Raffeld M, Eidelman O, Pollard HB, Bubendorf L. ANXA7 expression represents hormone-relevant tumor suppression in different cancers. Int J Cancer 2007; 121: 2628-2636 [PMID: 17708571 DOI: 10.1002/ijc.23008]
132. Srivastava M, Montagna C, Leighton X, Glasman M, Naga S, Eidelman O, Ried T, Pollard HB. Haploinsufficiency of Anx7 tumor suppressor gene and consequent genomic instability promotes tumorigenesis in the Anx7(+/-) mouse. Proc Natl Acad Sci USA 2003; 100: 14287-14292 [PMID: 14608035 DOI: 10.1073/pnas.2235927100]
133. Tauchi H, Matsuura S, Kobayashi J, Sakamoto S, Komatsu K. Nijmegen breakage syndrome gene, NBS1, and molecular links to factors for genome stability. Oncogene 2002; 21: 8967-8980 [PMID: 12483513 DOI: 10.1038/sj.onc.1206136]
134. Dumon-Jones V, Frappart PO, Tong WM, Sajithlal G, Hulla W, Schmid G, Herceg Z, Digweed M, Wang ZQ. Nbn heterozygosity renders mice susceptible to tumor formation and ionizing radiationinduced tumorigenesis. Cancer Res 2003; 63: 7263-7269 [PMID: 14612522]
135. Soohoo CY, Shi R, Lee TH, Huang P, Lu KP, Zhou XZ. Telomerase inhibitor PinX1 provides a link between TRF1 and telomerase to prevent telomere elongation. J Biol Chem 2011; 286: 3894-3906 [PMID: 21119197 DOI: 10.1074/jbc.M110.180174]
136. Liao C, Zhao M, Song H, Uchida K, Yokoyama KK, Li T. Identification of the gene for a novel liver-related putative tumor suppressor at a high-frequency loss of heterozygosity region of chromosome 8p23 in human hepatocellular carcinoma. Hepatology 2000; 32: 721-727 [PMID: 11003615 DOI: 10.1053/jhep.2000.17967]
137. Zhou XZ, Huang P, Shi R, Lee TH, Lu G, Zhang Z, Bronson R, Lu KP. The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice. J Clin Invest 2011; 121: 1266-1282 [PMID: 21436583 DOI: 10.1172/JCI43452]
138. Marston AL. Shugoshins: tension-sensitive pericentromeric adaptors safeguarding chromosome segregation. Mol Cell Biol 2015; 35: 634-648 [PMID: 25452306 DOI: 10.1128/MCB.01176-14]
139. Yamada HY, Zhang Y, Reddy A, Mohammed A, Lightfoot S, Dai W, Rao CV. Tumor-promoting/progressing role of additional chromosome instability in hepatic carcinogenesis in Sgo1 (Shugoshin 1) haploinsufficient mice. Carcinogenesis 2015; 36: 429-440 [PMID: 25740822 DOI: 10.1093/carcin/bgv011]
140. Wang LH, Yen CJ, Li TN, Elowe S, Wang WC, Wang LH. Sgo1 is a potential therapeutic target for hepatocellular carcinoma. Oncotarget 2015; 6: 2023-2033 [PMID: 25638162 DOI: 10.18632/oncotarget.2764]
141. Lade A, Noon LA, Friedman SL. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol 2014; 26: 100-107 [PMID: 24275855 DOI: 10.1097/CCO.0000000000000042]
142. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012; 56: 952-964 [PMID: 22173168 DOI: 10.1016/j.jhep.2011.08.025]
143. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656-665 [PMID: 24080776 DOI: 10.1038/nrgastro.2013.183]
144. Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-Activated receptor alpha natural ligand metabolism. J Biol Chem 1998; 273: 15639-15645 [PMID: 9624157 DOI: 10.1074/jbc.273.25.15639]
145. Anstee QM, Day CP. S-Adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol 2012; 57: 1097-1109 [PMID: 22659519 DOI: 10.1016/j.jhep.2012.04.041]
146. Lu SC, Mato JM. S-Adenosylmethionine in liver health, injury, and cancer. Physiol Rev 2012; 92: 1515-1542 [PMID: 23073625 DOI: 10.1152/physrev.00047.2011]
147. Mato JM, Martínez-Chantar ML, Lu SC. S-Adenosylmethionine metabolism and liver disease. Ann Hepatol 2013; 12: 183-189 [PMID: 23396728]
148. Chen YM, Shiu JY, Tzeng SJ, Shih LS, Chen YJ, Lui WY, Chen PH. Characterization of glycine-N-methyltransferase-gene expression in human hepatocellular carcinoma. Int J Cancer 1998; 75: 787-793 [PMID: 9495250 DOI: 10.1002/(SICI)1097-0215(19980302)75:53.0.CO;2-2]
149. Avila MA, Berasain C, Torres L, Martín-Duce A, Corrales FJ, Yang H, Prieto J, Lu SC, Caballería J, Rodés J, Mato JM. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol 2000; 33: 907-914 [PMID: 11131452 DOI: 10.1016/S0168-8278(00)81122-1]
150. Teng YW, Mehedint MG, Garrow TA, Zeisel SH. Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J Biol Chem 2011; 286: 36258-36267 [PMID: 21878621 DOI: 10.1074/jbc.M111.265348]
151. Martínez-Chantar ML, Vázquez-Chantada M, Ariz U, Martínez N, Varela M, Luka Z, Capdevila A, Rodríguez J, Aransay AM, Matthiesen R, Yang H, Calvisi DF, Esteller M, Fraga M, Lu SC, Wagner C, Mato JM. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 2008; 47: 1191-1199 [PMID: 18318442 DOI: 10.1002/hep.22159]
152. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147-191 [PMID: 19126757 DOI: 10.1152/physrev.00010.2008]
153. Baptissart M, Vega A, Maqdasy S, Caira F, Baron S, Lobaccaro JM, Volle DH. Bile acids: from digestion to cancers. Biochimie 2013; 95: 504-517 [PMID: 22766017 DOI: 10.1016/j.biochi.2012.06.022]
154. Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol 2013; 58: 155-168 [PMID: 22885388 DOI: 10.1016/j.jhep.2012.08.002]
155. Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007; 28: 940-946 [PMID: 17183066 DOI: 10.1093/carcin/bgl249]
156. Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, van den Bergh Weerman MA, Verkruisen RP, Groen AK, Oude Elferink RP, van der Valk MA, Borst P, Offerhaus GJ. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994; 145: 1237-1245 [PMID: 7977654]
157. Liu N, Meng Z, Lou G, Zhou W, Wang X, Zhang Y, Zhang L, Liu X, Yen Y, Lai L, Forman BM, Xu Z, Xu R, Huang W. Hepatocarcinogenesis in FXR-/-mice mimics human HCC progression that operates through HNF1? regulation of FXR expression. Mol Endocrinol 2012; 26: 775-785 [PMID: 22474109 DOI: 10.1210/me.2011-1383]
158. Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H, Trauner M. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 2005; 25: 367-379 [PMID: 15780063 DOI: 10.1111/j.1478-3231.2005.01033.x]
159. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005 [PMID: 20639898 DOI: 10.1038/onc.2010.236]
160. Nault JC, Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin Liver Dis 2011; 31: 173-187 [PMID: 21538283 DOI: 10.1055/s-0031-1276646]
161. Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol 2012; 56: 267-275 [PMID: 21782758 DOI: 10.1016/j.jhep.2011.07.007]
162. Ma Y, Yang Y, Wang F, Wei Q, Qin H. Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Int J Cancer 2015; 137: 2275-2286 [PMID: 25042563 DOI: 10.1002/ijc.29073]
163. Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep 2014; 15: 642-656 [PMID: 24825474 DOI: 10.15252/embr.201438638]
164. Yu FX, Meng Z, Plouffe SW, Guan KL. Hippo pathway regulation of gastrointestinal tissues. Annu Rev Physiol 2015; 77: 201-227 [PMID: 25293527 DOI: 10.1146/annurev-physiol-021014-071733]
165. Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, Chen Y, Park O, Chang J, Simpson RM, Wang CY, Gao B, Jiang J, Yang Y. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci USA 2010; 107: 1431-1436 [PMID: 20080598 DOI: 10.1073/pnas.0911409107]
166. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee JS, Johnson RL. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA 2010; 107: 1437-1442 [PMID: 20080689 DOI: 10.1073/pnas.0911427107]
167. Cooper J, Giancotti FG. Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett 2014; 588: 2743-2752 [PMID: 24726726 DOI: 10.1016/j.febslet.2014.04.001]
168. Benhamouche S, Curto M, Saotome I, Gladden AB, Liu CH, Giovannini M, McClatchey AI. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev 2010; 24: 1718-1730 [PMID: 20675406 DOI: 10.1101/gad.1938710]
169. Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, Giovannini M, Liu P, Anders RA, Pan D. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 2010; 19: 27-38 [PMID: 20643348 DOI: 10.1016/j.devcel.2010.06.015]
170. Quintás-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res 2013; 19: 1933-1940 [PMID: 23406773 DOI: 10.1158/1078-0432. CCR-12-0284]
171. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012; 30: 1005-1014 [PMID: 22355058 DOI: 10.1200/JCO.2010.31.8907]
172. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015; 66: 311-328 [PMID: 25587654 DOI: 10.1146/annurev-med-051113-024537]
173. Inagaki-Ohara K, Kondo T, Ito M, Yoshimura A. SOCS, inflammation, and cancer. JAKSTAT 2013; 2: e24053 [PMID: 24069550 DOI: 10.4161/jkst.24053]
174. Yoshida T, Ogata H, Kamio M, Joo A, Shiraishi H, Tokunaga Y, Sata M, Nagai H, Yoshimura A. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med 2004; 199: 1701-1707 [PMID: 15197228 DOI: 10.1084/jem.20031675]
175. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada T, Takeda K, Akira S, Hoshijima M, HIrano T, Chien KR, Yoshimura A. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003; 4: 551-556 [PMID: 12754507 DOI: 10.1038/ni938]
176. Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y, Koga K, Takaesu G, Maehara Y, Iida M, Yoshimura A. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitisinduced hepatocarcinogenesis. Gastroenterology 2006; 131: 179-193 [PMID: 16831601 DOI: 10.1053/j.gastro.2006.04.025]
177. Lehmann U, Schmitz J, Weissenbach M, Sobota RM, Hortner M, Friederichs K, Behrmann I, Tsiaris W, Sasaki A, Schneider-Mergener J, Yoshimura A, Neel BG, Heinrich PC, Schaper F. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem 2003; 278: 661-671 [PMID: 12403768 DOI: 10.1074/jbc.M210552200]
178. Nevzorova YA, Liedtke C. Sh(i)pping signals protect against Stat3-driven liver cancer. Hepatology 2012; 55: 322-324 [PMID: 22190379 DOI: 10.1002/hep.24742]
179. Bard-Chapeau EA, Li S, Ding J, Zhang SS, Zhu HH, Princen F, Fang DD, Han T, Bailly-Maitre B, Poli V, Varki NM, Wang H, Feng GS. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 2011; 19: 629-639 [PMID: 21575863 DOI: 10.1016/j.ccr.2011.03.023]
180. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007; 117: 2713-2722 [PMID: 17717605 DOI: 10.1172/JCI31457]
181. Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng L, Huang X, Wang X, Sun B. Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology 2013; 57: 678-688 [PMID: 22821478 DOI: 10.1002/hep.25980]
182. Zhang W, Hou J, Wang X, Jiang R, Yin Y, Ji J, Deng L, Huang X, Wang K, Sun B. PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis. Oncotarget 2015; 6: 9420-9433 [PMID: 25826083 DOI: 10.18632/oncotarget.3353]
183. Luedde T, Schwabe RF. NF-?B in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8: 108-118 [PMID: 21293511 DOI: 10.1038/nrgastro.2010.213]
184. Qiao L, Zhang H, Yu J, Francisco R, Dent P, Ebert MP, Röcken C, Farrell G. Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. Hum Gene Ther 2006; 17: 280-290 [PMID: 16544977 DOI: 10.1089/hum.2006.17.280]
185. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-?B addiction and its role in cancer: 'one size does not fit all'. Oncogene 2011; 30: 1615-1630 [PMID: 21170083 DOI: 10.1038/onc.2010.566]
186. He G, Karin M. NF-?B and STAT3-key players in liver inflammation and cancer. Cell Res 2011; 21: 159-168 [PMID: 21187858 DOI: 10.1038/cr.2010.183]
187. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 2010; 17: 25-34 [PMID: 19373246 DOI: 10.1038/cdd.2009.43]
188. Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R, Bosserhoff AK. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 2007; 28: 21-27 [PMID: 16774947 DOI: 10.1093/carcin/bgl081]
189. Nikolaou K, Tsagaratou A, Eftychi C, Kollias G, Mosialos G, Talianidis I. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 2012; 21: 738-750 [PMID: 22698400 DOI: 10.1016/j.ccr.2012.04.026]
190. Liu L, Sakai T, Sano N, Fukui K. Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling. Biochem J 2004; 380: 31-41 [PMID: 14961764 DOI: 10.1042/BJ20031300]
191. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009; 230: 160-171 [PMID: 19594635 DOI: 10.1111/j.1600-065X.2009.00794.x]
192. Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 2008; 38: 1098-1111 [PMID: 18684128 DOI: 10.1111/j.1872-034X.2008.00387.x]
193. Nomoto K, Tsuneyama K, Abdel Aziz HO, Takahashi H, Murai Y, Cui ZG, Fujimoto M, Kato I, Hiraga K, Hsu DK, Liu FT, Takano Y. Disrupted galectin-3 causes non-Alcoholic fatty liver disease in male mice. J Pathol 2006; 210: 469-477 [PMID: 17029217 DOI: 10.1002/path.2065]
194. Nakanishi Y, Tsuneyama K, Nomoto K, Fujimoto M, Salunga TL, Nakajima T, Miwa S, Murai Y, Hayashi S, Kato I, Hiraga K, Hsu DK, Liu FT, Takano Y. Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. Hepatol Res 2008; 38: 1241-1251 [PMID: 18637146 DOI: 10.1111/j.1872-034X.2008.00395.x]
195. Aigelsreiter A, Haybaeck J, Schauer S, Kiesslich T, Bettermann K, Griessbacher A, Stojakovic T, Bauernhofer T, Samonigg H, Kornprat P, Lackner C, Pichler M. NEMO expression in human hepatocellular carcinoma and its association with clinical outcome. Hum Pathol 2012; 43: 1012-1019 [PMID: 22176836 DOI: 10.1016/j.humpath.2011.08.009]
196. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11: 119-132 [PMID: 17292824 DOI: 10.1016/j.ccr.2006.12.016]
197. Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F, Weber A, Weiskirchen R, Liedtke C, Gassler N, Müller M, de Vos R, Wolf MJ, Boege Y, Seleznik GM, Zeller N, Erny D, Fuchs T, Zoller S, Cairo S, Buendia MA, Prinz M, Akira S, Tacke F, Heikenwalder M, Trautwein C, Luedde T. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell 2010; 17: 481-496 [PMID: 20478530 DOI: 10.1016/j.ccr.2010.03.021]
198. Bhat M, Sonenberg N, Gores GJ. The mTOR pathway in hepatic malignancies. Hepatology 2013; 58: 810-818 [PMID: 23408390 DOI: 10.1002/hep.26323]
199. Polivka J, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 2014; 142: 164-175 [PMID: 24333502 DOI: 10.1016/j.pharmthera.2013.12.004]
200. Hezel AF, Bardeesy N. LKB1; linking cell structure and tumor suppression. Oncogene 2008; 27: 6908-6919 [PMID: 19029933 DOI: 10.1038/onc.2008.342]
201. Miyoshi H, Deguchi A, Nakau M, Kojima Y, Mori A, Oshima M, Aoki M, Taketo MM. Hepatocellular carcinoma development induced by conditional beta-catenin activation in Lkb1+/-mice. Cancer Sci 2009; 100: 2046-2053 [PMID: 19671058 DOI: 10.1111/j.1349-7006.2009.01284.x]
202. Nakau M, Miyoshi H, Seldin MF, Imamura M, Oshima M, Taketo MM. Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout mice. Cancer Res 2002; 62: 4549-4553 [PMID: 12183403]
203. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008; 133: 403-414 [PMID: 18455982 DOI: 10.1016/j.cell.2008.04.013]
204. Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, Changchien CS, Lee CM, Tai MH. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003; 97: 1929-1940 [PMID: 12673720 DOI: 10.1002/cncr.11266]
205. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19: 348-355 [PMID: 9697695 DOI: 10.1038/1235]
206. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M, Mak TW. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998; 8: 1169-1178 [PMID: 9799734 DOI: 10.1016/S0960-9822(07)00488-5]
207. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999; 96: 1563-1568 [PMID: 9990064 DOI: 10.1073/pnas.96.4.1563]
208. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, Naito M, Enomoto K, Watanabe S, Mak TW, Nakano T. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004; 113: 1774-1783 [PMID: 15199412 DOI: 10.1172/JCI200420513]
209. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-1983, 1983.e1-11 [PMID: 18929564 DOI: 10.1053/j.gastro.2008.08.008]
210. Umemura A, Park EJ, Taniguchi K, Lee JH, Shalapour S, Valasek MA, Aghajan M, Nakagawa H, Seki E, Hall MN, Karin M. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab 2014; 20: 133-144 [PMID: 24910242 DOI: 10.1016/j.cmet.2014.05.001]
211. Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L, Farci P, Mishra L. Hepatic stem cells and transforming growth factor ? in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2012; 9: 530-538 [PMID: 22710573 DOI: 10.1038/nrgastro.2012.114]
212. Inman GJ. Switching TGF? from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev 2011; 21: 93-99 [PMID: 21251810 DOI: 10.1016/j.gde.2010.12.004]
213. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C, Grippo PJ. TGF-?: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst 2014; 106: djt369 [PMID: 24511106 DOI: 10.1093/jnci/djt369]
214. Kitisin K, Ganesan N, Tang Y, Jogunoori W, Volpe EA, Kim SS, Katuri V, Kallakury B, Pishvaian M, Albanese C, Mendelson J, Zasloff M, Rashid A, Fishbein T, Evans SR, Sidawy A, Reddy EP, Mishra B, Johnson LB, Shetty K, Mishra L. Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene 2007; 26: 7103-7110 [PMID: 17546056 DOI: 10.1038/sj.onc.1210513]
215. Russell WE, Coffey RJ, Ouellette AJ, Moses HL. Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci USA 1988; 85: 5126-5130 [PMID: 3164865 DOI: 10.1073/pnas.85.14.5126]
216. Tang B, Böttinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR, Letterio JJ, Wakefield LM. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 1998; 4: 802-807 [PMID: 9662371 DOI: 10.1038/nm0798-802]
217. Kiss A, Wang NJ, Xie JP, Thorgeirsson SS. Analysis of transforming growth factor (TGF)-Alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997; 3: 1059-1066 [PMID: 9815784]
218. Im YH, Kim HT, Kim IY, Factor VM, Hahm KB, Anzano M, Jang JJ, Flanders K, Haines DC, Thorgeirsson SS, Sizeland A, Kim SJ. Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis. Cancer Res 2001; 61: 6665-6668 [PMID: 11559531]
219. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653: 1-24 [PMID: 12781368 DOI: 10.1016/S0304-419X(03)00005-2]
220. Monga SP. Role of Wnt/?-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol 2011; 43: 1021-1029 [PMID: 19747566 DOI: 10.1016/j.biocel.2009.09.001]
221. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11-26 [PMID: 23258168 DOI: 10.1038/nrc3419]
222. Csepregi A, Röcken C, Hoffmann J, Gu P, Saliger S, Müller O, Schneider-Stock R, Kutzner N, Roessner A, Malfertheiner P, Ebert MP. APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134: 579-589 [PMID: 17973119 DOI: 10.1007/s00432-007-0321-y]
223. Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, Giovannini M, Perret C. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci USA 2004; 101: 17216-17221 [PMID: 15563600 DOI: 10.1073/pnas.0404761101]
224. Callegari E, Gramantieri L, Domenicali M, D'Abundo L, Sabbioni S, Negrini M. MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ 2015; 22: 46-57 [PMID: 25190143 DOI: 10.1038/cdd.2014.136]
225. George J, Patel T. Noncoding RNA as therapeutic targets for hepatocellular carcinoma. Semin Liver Dis 2015; 35: 63-74 [PMID: 25632936 DOI: 10.1055/s-0034-1397350]
226. Yang N, Ekanem NR, Sakyi CA, Ray SD. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics. Adv Drug Deliv Rev 2015; 81: 62-74 [PMID: 25450260 DOI: 10.1016/j.addr.2014.10.029]
227. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, Jacob ST, Ghoshal K. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99: 671-678 [PMID: 16924677 DOI: 10.1002/jcb.20982]
228. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS, Hsiao M, Tsou AP. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122: 2884-2897 [PMID: 22820290 DOI: 10.1172/JCI63455]
229. Takata A, Otsuka M, Yoshikawa T, Kishikawa T, Hikiba Y, Obi S, Goto T, Kang YJ, Maeda S, Yoshida H, Omata M, Asahara H, Koike K. MicroRNA-140 acts as a liver tumor suppressor by controlling NF-?B activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression. Hepatology 2013; 57: 162-170 [PMID: 22898998 DOI: 10.1002/hep.26011]
230. Sauvé F, McBroom LD, Gallant J, Moraitis AN, Labrie F, Giguére V. CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol Cell Biol 2001; 21: 343-353 [PMID: 11113208 DOI: 10.1128/MCB.21.1.343-353.2001]
231. Gao S, Li A, Liu F, Chen F, Williams M, Zhang C, Kelley Z, Wu CL, Luo R, Xiao H. NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. Cancer Cell 2013; 24: 725-737 [PMID: 24332041 DOI: 10.1016/j.ccr.2013.11.005]
232. Bossis I, Stratakis CA. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology 2004; 145: 5452-5458 [PMID: 15331577 DOI: 10.1210/en.2004-0900]
233. Veugelers M, Wilkes D, Burton K, McDermott DA, Song Y, Goldstein MM, La Perle K, Vaughan CJ, O'Hagan A, Bennett KR, Meyer BJ, Legius E, Karttunen M, Norio R, Kaariainen H, Lavyne M, Neau JP, Richter G, Kirali K, Farnsworth A, Stapleton K, Morelli P, Takanashi Y, Bamforth JS, Eitelberger F, Noszian I, Manfroi W, Powers J, Mochizuki Y, Imai T, Ko GT, Driscoll DA, Goldmuntz E, Edelberg JM, Collins A, Eccles D, Irvine AD, McKnight GS, Basson CT. Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. Proc Natl Acad Sci USA 2004; 101: 14222-14227 [PMID: 15371594 DOI: 10.1073/pnas.0405535101]
234. Chopra AR, Louet JF, Saha P, An J, Demayo F, Xu J, York B, Karpen S, Finegold M, Moore D, Chan L, Newgard CB, O'Malley BW. Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science 2008; 322: 1395-1399 [PMID: 19039140 DOI: 10.1126/science.1164847]
235. O'Donnell KA, Keng VW, York B, Reineke EL, Seo D, Fan D, Silverstein KA, Schrum CT, Xie WR, Mularoni L, Wheelan SJ, Torbenson MS, O'Malley BW, Largaespada DA, Boeke JD. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. Proc Natl Acad Sci USA 2012; 109: E1377-E1386 [PMID: 22556267 DOI: 10.1073/pnas.1115433109]
236. Chen L, Kwong M, Lu R, Ginzinger D, Lee C, Leung L, Chan JY. Nrf1 is critical for redox balance and survival of liver cells during development. Mol Cell Biol 2003; 23: 4673-4686 [PMID: 12808106 DOI: 10.1128/MCB.23.13.4673-4686.2003]
237. Hirotsu Y, Hataya N, Katsuoka F, Yamamoto M. NF-E2-related factor 1 (Nrf1) serves as a novel regulator of hepatic lipid metabolism through regulation of the Lipin1 and PGC-1? genes. Mol Cell Biol 2012; 32: 2760-2770 [PMID: 22586274 DOI: 10.1128/MCB.06706-11]
238. Xu Z, Chen L, Leung L, Yen TS, Lee C, Chan JY. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci USA 2005; 102: 4120-4125 [PMID: 15738389 DOI: 10.1073/pnas.0500660102]
239. Vilarinho S, Calvisi DF. New advances in precision medicine for hepatocellular carcinoma recurrence prediction and treatment. Hepatology 2014; 60: 1812-1814 [PMID: 25042754 DOI: 10.1002/hep.27311]
240. Shanker M, Jin J, Branch CD, Miyamoto S, Grimm EA, Roth JA, Ramesh R. Tumor suppressor gene-based nanotherapy: from test tube to the clinic. J Drug Deliv 2011; 2011: 465845 [PMID: 21490751 DOI: 10.1155/2011/465845]
241. Burk RD, DeLoia JA, elAwady MK, Gearhart JD. Tissue preferential expression of the hepatitis B virus (HBV) surface antigen gene in two lines of HBV transgenic mice. J Virol 1988; 62: 649-654 [PMID: 2826823]
242. Qin LF, Ng IO. Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis. Hum Pathol 2001; 32: 778-784 [PMID: 11521219 DOI: 10.1053/hupa.2001.27105]
243. Zhang MF, Zhang ZY, Fu J, Yang YF, Yun JP. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med 2009; 7: 110 [PMID: 20025780 DOI: 10.1186/1479-5876-7-110]
244. Wang Y, Li M, Long J, Shi XY, Li Q, Chen J, Tong WM, Jia JD, Huang J. Clinical significance of increased expression of Nijmegen breakage syndrome gene (NBS1) in human primary liver cancer. Hepatol Int 2014; 8: 250-259 [PMID: 26202506 DOI: 10.1007/s12072-013-9500-x]
245. Abou-Shady M, Baer HU, Friess H, Berberat P, Zimmermann A, Graber H, Gold LI, Korc M, Büchler MW. Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am J Surg 1999; 177: 209-215 [PMID: 10219856 DOI: 10.1016/S0002-9610(99)00012-4]
246. Chaerkady R, Harsha HC, Nalli A, Gucek M, Vivekanandan P, Akhtar J, Cole RN, Simmers J, Schulick RD, Singh S, Torbenson M, Pandey A, Thuluvath PJ. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. J Proteome Res 2008; 7: 4289-4298 [PMID: 18715028 DOI: 10.1021/pr800197z]